Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Functional analysis of BRCA1 missense variants of uncertain significance in Japanese breast cancer families.

Kawaku S, Sato R, Song H, Bando Y, Arinami T, Noguchi E.

J Hum Genet. 2013 Sep;58(9):618-21. doi: 10.1038/jhg.2013.71. Epub 2013 Jul 11.

PMID:
23842040
2.

BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.

Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P.

Dis Markers. 2012;32(6):343-53. doi: 10.3233/DMA-2012-0893.

3.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

4.

Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.

Surowy HM, Sutter C, Mittnacht M, Klaes R, Schaefer D, Evers C, Burgemeister AL, Goehringer C, Dikow N, Heil J, Golatta M, Schott S, Schneeweiss A, Bugert P, Sohn C, Bartram CR, Burwinkel B.

Breast Cancer Res Treat. 2014 Jun;145(2):451-60. doi: 10.1007/s10549-014-2943-5. Epub 2014 Apr 12.

PMID:
24728577
6.

Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.

Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP.

Hum Mutat. 2003 Aug;22(2):121-8.

PMID:
12872252
7.
8.

Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.

Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau C, King MC, Camus M, Alvarez M, Carvallo P.

Breast Cancer Res Treat. 2006 Jan;95(1):81-7. Epub 2005 Oct 27.

PMID:
16261400
9.

BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy.

Ang P, Lim IH, Lee TC, Luo JT, Ong DC, Tan PH, Lee AS.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2276-84.

10.

BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.

Claes K, Poppe B, Coene I, Paepe AD, Messiaen L.

Br J Cancer. 2004 Mar 22;90(6):1244-51.

11.

High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.

Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C, Matous B.

Breast Cancer Res. 2005;7(5):R728-36. Epub 2005 Jul 19.

12.

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A.

Breast Cancer Res Treat. 2006 Nov;100(1):83-91. Epub 2006 May 9.

PMID:
16847550
13.

Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.

Valarmathi MT, Sawhney M, Deo SS, Shukla NK, Das SN.

Hum Mutat. 2004 Feb;23(2):205.

PMID:
14722926
14.

BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.

Tazzite A, Jouhadi H, Nadifi S, Aretini P, Falaschi E, Collavoli A, Benider A, Caligo MA.

Gynecol Oncol. 2012 Jun;125(3):687-92. doi: 10.1016/j.ygyno.2012.03.007. Epub 2012 Mar 13.

PMID:
22425665
15.

A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.

Machácková E, Foretová L, Navrátilová M, Valík D, Claes K, Messiaen L.

Cas Lek Cesk. 2000 Oct 11;139(20):635-7.

PMID:
11192759
16.

[Clinical aspects of familial ovarian cancer - current status and issues in Japan].

Sekine M, Yoshihara K, Tanaka K.

Gan To Kagaku Ryoho. 2012 Apr;39(4):506-11. Japanese.

PMID:
22504673
17.

Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.

Dombernowsky SL, Weischer M, Freiberg JJ, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG.

Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2339-42. doi: 10.1158/1055-9965.EPI-09-0447. Erratum in: Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1661.

18.

BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.

Delgado L, Fernández G, Grotiuz G, Cataldi S, González A, Lluveras N, Heguaburu M, Fresco R, Lens D, Sabini G, Muse IM.

Breast Cancer Res Treat. 2011 Jul;128(1):211-8. doi: 10.1007/s10549-010-1320-2. Epub 2010 Dec 29.

PMID:
21190077
19.

Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.

Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC.

Breast Cancer Res Treat. 2004 Nov;88(2):177-86.

PMID:
15564800
20.

Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G; Kathleen Cuningham Consortium for Research in Familial Breast Cancer.

Breast Cancer Res. 2006;8(1):R12. Epub 2006 Feb 13.

Supplemental Content

Support Center